Litigation Details for IMMUNEX CORPORATION v. SANDOZ INC. (D.N.J. 2016)
✉ Email this page to a colleague
IMMUNEX CORPORATION v. SANDOZ INC. (D.N.J. 2016)
| Docket | ⤷ Sign Up | Date Filed | 2016-02-25 |
| Court | District Court, D. New Jersey | Date Terminated | 2019-10-08 |
| Cause | 35:271 Patent Infringement | Assigned To | Claire Claudia Cecchi |
| Jury Demand | Both | Referred To | Mark Falk |
| Parties | SANDOZ INTERNATIONAL GMBH | ||
| Patents | 7,915,225 | ||
| Attorneys | JAMES S. RICHTER | ||
| Firms | Counsel Not Admitted to Usdc-Nj Bar, Phillips Adr Enterprises | ||
| Link to Docket | External link to docket | ||
Biologic Drugs cited in IMMUNEX CORPORATION v. SANDOZ INC.
The biologic drug covered by the patent cited in this case is ⤷ Sign Up .
Details for IMMUNEX CORPORATION v. SANDOZ INC. (D.N.J. 2016)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2016-02-25 | 1 | Complaint | the ’522 patent”), 7,915,225 (“the ’225 patent”), 8,119,605 (“the ’605 patent”), and 8,722,631 (“the …arthritis. The ’225 patent, the ’605 patent, and the ’631 patent (“the Psoriasis Patents”), owned by Immunex… The asserted patents are United States Patent Nos. 8,063,182 (“the ’182 patent”), 8,163,522 (“the…the ’631 patent”) (collectively, “the patents-in-suit”). 11. Roche is the owner of the ’182 …to the ’182 and ’522 patents, an exclusive sublicense) to the asserted patents. 14. On September | External link to document |
| 2016-10-28 | 125 | Redacted Document | the ‘522 patent”), 7,915,225 (“the ‘225 patent”), 8,119,605 (“the ‘605 patent”), and 8,722,631 (“the …of U.S. Patent Nos. 8,063,182 (“the ‘182 patent”); 8,163,522 (“the ‘522 patent”); 7,915,225 (“the ‘225…arthritis. The ‘225 patent, the ‘605 patent, and the ‘631 patent (“the Psoriasis Patents”), owned by Immunex…. The asserted patents are United States Patent Nos. 8,063,182 (“the ‘182 patent”), 8,163,522 (“the…‘225 patent”); 8,119,605 (“the ‘605 patent”); and 8,722,631 (“the ‘631 patent”). 11. Roche | External link to document |
| 2016-11-30 | 133 | Markman Opening Brief | ’225 Patent US Patent No. 7,915,225 ’605 Patent US Patent No. 8,119,605 ’631 Patent…Wall, Ph.D. ’182 Patent US Patent No. 8,063,182 ’522 Patent US Patent No. 8,163,522 ’…Reference Patent Office United States Patent and Trademark Office PTAB Patent Trial …owns the patent granted on this novel fusion protein (“the ’182 Patent”), as well as the patent that claims… ’605, and ’631 Patents”) (the “Immunex Patents”). Roche licensed the Roche Patents to Immunex, which | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
